Compounded Fentanyl-Ropivacaine Epidural Injection Recalled Due to Sterility Assurance Concerns
QuVa Pharma is recalling 1,765 cassettes of compounded epidural injection due to lack of sterility assurance. The affected lots were distributed nationwide to institutional and office locations.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a high-risk injectable product (epidural injection) due to lack of sterility assurance. The source text does not report any associated illnesses, injuries, or deaths, placing this as a risk-of-harm scenario without reported injury.
Plain-English summary
QuVa Pharma, Inc. is recalling 1,765 cassettes of fentaNYL Citrate PF 200 mcg/100 mL / 0.2% ROPivacaine HCl 200 mg/100 mL in 100 mL NS Yellow CADD FSFF injection for epidural use. This is a compounded product intended for institutional or office use only.
The recall was issued due to lack of assurance of sterility. The affected lots are Lot 10140303 (expiring 04/14/2025), Lots 10140867 and 10140868 (expiring 04/24/2025), and Lot 10140965 (expiring 04/28/2025). These products were distributed nationwide.
Healthcare providers who have received the affected lots should contact QuVa Pharma, Inc. for further instructions regarding the recalled product.
The recalled product
- Product
- fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.2% ROPivacaine HCl 200 mg/100 mL (2 mg/mL), 100 ml in NS Yellow CADD FSFF, Injection for Epidural Use (Not intended For IV Use), Compounded, For Institutional or Office Use Only, QuVa Pharma, 1075 West Park One Drive, Suite 100, Su
- Manufacturer
- QuVa Pharma, Inc.
- Category
- Drug — Injectable / Compounded
- Affected units
- 1,765
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot
- expiry: Lot 10140303
- exp 04/14/2025
- Lots 10140867
- 10140868
- exp 04/24/2025
- Lot 10140965
- exp 04/28/2025
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by QuVa Pharma, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · QuVa Pharma, Inc.
See all →- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- HighCompounded pain injection syringes recalled over presence of particulate matter
FDA (Drugs) · 2025-11-05
- HighCompounded Fentanyl and Bupivacaine Epidural Injections Recalled for Sterility Assurance
FDA (Drugs) · 2025-04-02
- HighCompounded Fentanyl-Bupivacaine Epidural Injections Recalled for Sterility Failure
FDA (Drugs) · 2025-04-02
- HighOxytocin injection recalled for incorrect sodium chloride concentration
FDA (Drugs) · 2022-10-05
Same hazard · sterility assurance
See all →- HighArrowhead DE LLC Recalls Arrow-LOK Implants Due to Sterility Assurance Concerns
FDA (Devices) · 2026-08-26
- SevereChloraPrep One-Step Applicators Recalled for Potential Packaging Seal Defects
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- SevereChloraPrep One-Step Applicators Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2026-07-08
- SevereArrow drainage and thoracentesis kits contain recalled supplier drugs
FDA (Devices) · 2026-06-24